Review Article

Endothelial dysfunction: the early predictor of atherosclerosis

MASHUDU MUDAU, AMANDA GENIS, AMANDA LOCHNER, HANS STRIJDOM

Abstract

Since the discovery in the 1980s that nitric oxide (NO) is in fact the elusive endothelium-derived relaxing factor, it has become evident that NO is not only a major cardiovascular signalling molecule, but that changes in its bioavailability are crucial in determining whether atherosclerosis will develop or not. Sustained high levels of harmful circulating stimuli associated with cardiovascular risk factors such as diabetes mellitus elicit responses in endothelial cells that appear sequentially, namely endothelial cell activation and endothelial dysfunction (ED).

ED, characterised by reduced NO bioavailability, is now recognised by many as an early, reversible precursor of atherosclerosis. The pathogenesis of ED is multifactorial; however, oxidative stress appears to be the common underlying cellular mechanism in the ensuing loss of vaso-active, inflammatory, haemostatic and redox homeostasis in the body’s vascular system. The role of ED as a pathophysiological link between early endothelial cell changes associated with cardiovascular risk factors and the development of ischaemic heart disease is of importance to basic scientists and clinicians alike.

Keywords: endothelium, endothelial dysfunction, nitric oxide bioavailability, eNOS uncoupling, oxidative stress, atherosclerosis

EXPOSURE TO CARDIOVASCULAR RISK FACTORS:
• Hyperglycaemia/insulin resistance (diabetes mellitus)
• Smoking
• Hypertension
• Obesity
• Hyperlipidaemia

If sustained and not reversed

DEVELOPMENT OF ENDOTHELIAL CELL CHANGES:
• Endothelial activation
• Endothelial dysfunction
Associated with reduced NO bioavailability; pro-vasoconstriction; pro-oxidative stress; pro-coagulation; pro-inflammation

If sustained and not reversed

PROGRESSION TO ATHEROSCLEROSIS:
• Plaque formation and sequelae
• Myocardial ischaemia
• Myocardial infarction

Fig. 1. Exposure of endothelial cells to cardiovascular risk factors and the resultant pathophysiological changes, i.e. endothelial activation and dysfunction, with progression to atherosclerosis if risk-factor exposure is sustained.
initiate vasodilation in response to vasodilatory stimuli such as acetylcholine or shear stress. It represents an initial reversible step in the development of atherogenesis, and for this reason, early clinical identification of ED may become an important tool in the prevention or reversal of progression to atherosclerosis and IHD.  

ED comprises a loss of balance between endothelial-derived vasodilatory and vasoconstrictory factors, where the pro-vasoconstrictory state becomes dominant, leading to progressive pathophysiological changes. These changes appear as sequentially occurring responses in endothelial cells, also referred to by some as the endothelial activation–dysfunction–injury triad. Collectively, these endothelial changes exhibit pro-inflammatory, pro-oxidant, proliferative, pro-coagulation and pro-vascular adhesion features.  

The endothelium: a functional organ

The vascular endothelium consists of approximately 1–6 × 10^13 endothelial cells and accounts for about 1 kg of total body weight. For many years after its discovery, the endothelium was believed to be an inert, semi-permeable barrier between circulating blood and the underlying sub-endothelial tissues. However, extensive research has since revealed a far more complex role for the endothelium. We now know that the endothelium is in fact a metabolically active organ, playing a crucial role in the maintenance of vascular homeostasis by releasing a variety of vasoactive factors that can either dilate or constrict the blood vessels, depending on the type of the stimulus.  

Vascular homeostasis entails keeping a tightly controlled balance between a vasodilatory state, which is often associated with anti-oxidant, anti-inflammatory and anti-thrombotic effects on one hand, and a vasoconstrictory state on the other, which is associated with pro-oxidant, pro-inflammatory and pro-thrombotic effects. The vasodilatory state is mediated by factors such as nitric oxide (NO), endothelium-derived hyperpolarising factor (EDHF) and prostacyclins, while a vasoconstrictory state is mediated by factors such as endothelin-1 (ET-1), angiotensin II and thromboxane A2. Of these endothelial-derived factors, NO, which was originally identified as the endothelial-derived relaxing factor (EDRF), has since evoked much interest as it is considered to be the most potent endogenously synthesised vasodilator in the body, and a key marker of endothelial function and dysfunction.

The vasoactive factors released by endothelial cells and their effects are summarised in Table 1. In view of the physiological, pathophysiological and clinical importance of NO in vascular physiology, we have included a brief discussion on the physiology of NO below.

### Nitric oxide

The realisation in the 1980s that the identity of EDRF was in fact NO was rather astonishing, as NO had until then been perceived as nothing more than a toxic environmental pollutant found in cigarette smoke, exhaust fumes of motor cars and harmful gases generated by industrial processes. The ground-breaking discovery that NO is also synthesised in the body and functions as a chemical messenger with important physiological effects introduced a novel paradigm in cardiovascular physiology and pathophysiology. In addition to its vasodilatory properties, NO was also found to exert anti-inflammatory and cardioprotective effects.  

Owing to its gaseous and free-radical nature, NO is able to diffuse easily between cells and tissues and react with a variety of molecules in the body. NO is synthesised from the amino acid L-arginine by a family of enzymes known as nitric oxide synthase (NOS). The NOS enzyme occurs as

### TABLE 1. OVERVIEW OF ENDOTHELIUM-DERIVED VASO-ACTIVE FACTORS

| Endothelium-derived factors | Physiological effects | Enzymatic source and mechanism of action |
|-----------------------------|-----------------------|----------------------------------------|
| Nitric oxide (NO)           | • Potent vasodilator   | • Synthesised by the enzymes: eNOS, nNOS, iNOS, with eNOS the major endothelial source of NO during physiological conditions |
|                             | • Inhibits inflammation, VSMC proliferation and migration, platelet aggregation and adhesion, and leucocyte adhesion | • Diffuses from endothelial cells to underlying VSMCs where it binds to soluble guanylyl cyclase, leading to a cascade of events that ultimately result in vascular relaxation |
|                             | • Regulates myocardial contractility | • Derived from arachidonic acid by cyclooxygenase-2 (COX-2) |
|                             | • Regulates cardiac metabolism | • Its identity is still under suspicion with proposed candidates such as potassium ions and hydrogen peroxide |
|                             | • Cardioprotective during ischaemia–reperfusion injury | • Causes relation of VSMCs by means of membrane hyperpolarisation |
| Prostacyclin (PGI₂)         | • Vasodilatory agent   | • Synthesised by endothelin-converting enzyme |
|                             | • Inhibits platelet aggregation | • Exerts its effects via two receptors: ET, expressed on endothelial cells and ET, on VSMCs. ET, receptors promote vasoconstriction, whereas ET, receptors promote NO production and ultimately reduce in ET-1 production |
| Endothelium-derived hyperpolarising factor (EDHF) | • Exerts vasodilatory effects, particularly in small arteries of diameter ≤ 300 μm | • Derived from arachidonic acid by COX-1 |
| Endothelin-1 (ET-1)         | • A potent vasoconstrictor | • Synthesised by angiotensin converting enzyme |
| Thromboxane A (TXA₂)       | • A potent vasoconstrictor | • Elicits its effects via two receptors: AT, which promotes vasoconstriction and cell proliferation, and AT, which antagonises the effects of AT, |
| Angiotensin II             | • A potent vasoconstrictor | |

---

*AFRICA CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 4, May 2012*
Of the three isoforms, it has been proposed that flavin mononucleotide (FMN), and iron protoporphyrin IX tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), about 1 000-fold more than eNOS or nNOS. This can have inflammatory cytokines, and it produces large amounts of NO, iNOS is calcium independent, its expression is provoked by and continuously produce low levels of NO. On the other hand, eNOS and nNOS are constitutive, calcium-dependent enzymes.

endothelial cells in particular, leading to the classical signalling under physiological conditions in the cardiovascular system and eNOS is the major isoform responsible for NO production.14,16,17 Physiologically, all NOS isoforms require cofactors such as (6R)-5,6,7,8-tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and iron protoporphyrin IX (haem).18 Of the three isoforms, it has been proposed that eNOS is the major isoform responsible for NO production under physiological conditions in the cardiovascular system and endothelial cells in particular, leading to the classical signalling mechanism in the underlying vascular smooth muscle cells (VSMCs) and ultimately, relaxation.24 (Fig. 2).

Failure of the eNOS protein to dimerise, or the absence of some of the cofactors mentioned above will lead to the enzyme catalysing the formation of \( \text{O}_2^- \) instead of NO, a mechanism referred to as eNOS uncoupling.20 (Fig. 3). As will be discussed later, eNOS uncoupling is an important mediator of ED during a pathophysiological state.

Cardiovascular risk factors associated with the development of ED

Type 1 diabetes mellitus and insulin resistance/type 2 diabetes mellitus

Both type 1 and type 2 diabetes are independent risk factors for the development of accelerated atherosclerosis, IHD and cardiovascular disease in general.11 Similarly, type 1 diabetes mellitus, insulin resistance and type 2 diabetes mellitus have been shown to be strongly associated with the development of ED.23 In fact, the temporal progression from insulin resistance to type 2 diabetes mellitus has been postulated to be mirrored by the progression of ED to atherosclerosis.22

ED observed in diabetes mellitus is primarily attributable to (1) oxidative stress (increased \( \text{O}_2^- \) generation due to upregulated expression of NADPH oxidase), and (2) increased formation of advanced glycation end-products (AGEs).23,24 Aside from scavenging NO, causing decreased NO bioavailability and producing peroxynitrite, \( \text{O}_2^- \) also modifies the activity and regulation of eNOS, and promotes vascular smooth muscle cell (VSMC) proliferation and inflammation.24

Hyperglycaemia, as occurs in diabetes mellitus, results in non-enzymatic glycation of intracellular and extracellular proteins and lipids, which leads to the generation of AGEs. The latter subsequently accumulate in the vascular wall and reduce NO activity by quenching NO.24,25 AGEs also bind to specific surface receptors, called receptors for AGEs (RAGE), which are expressed on cells such as monocytes, macrophages and VSMCs, resulting in the amplification of an inflammatory response,24,25 increased vascular permeability and oxidative stress.25

Fig. 2. Synthesis of NO, downstream mechanisms and physiological effects. NO is synthesised by eNOS in the endothelial cells and diffuses into the underlying vascular smooth muscle cells (VSMCs), where it activates the second messenger, cyclic guanosine monophosphate (cGMP). Further downstream, signalling eventually leads to VSMD relaxation and vasodilation. In addition, NO regulates vascular homeostasis by anti-oxidation, anti-inflammatory and anti-platelet aggregation effects.

Fig. 3. Coupled and uncoupled eNOS. (A) In the presence of sufficient levels of substrates and co-factors, and the absence of harmful reactive species, eNOS monomers will form a dimerised, coupled enzyme and produce physiological amounts of NO. (B) Decreased levels of the substrate, L-arginine and/or harmful effects exerted by increased levels of ONOO-, cause failure of the enzyme to dimerise, leading to the uncoupling of eNOS and the production of \( \text{O}_2^- \) instead of NO.
Furthermore, hyperglycaemia is also known to activate protein kinase C (PKC), which decreases eNOS activity, leading to reduced NO and increased ET-1 production. In the setting of ED, ET-1, receptor-mediated vasodilatory effects of ET-1 are blunted (refer to Table 1) and therefore the vasoconstrictory state predominates. PKC also enhances the expression of adhesion molecules such as ICAM, VCAM and E-selectin, which is associated with endothelial cell activation.

ED has been reported to occur early in insulin resistance. Often insulin resistance is associated with central adiposity and hence the metabolic syndrome, i.e. hypertriglyceridaemia, low high-density lipoprotein (HDL) levels, high low-density lipoprotein (LDL) levels and hypertension, all of which could potentially favour the development of ED and eventually atherosclerosis.

**Hyperlipidaemia**

Hyperlipidaemia constitutes increased circulating lipids including cholesterol and triglycerides, a state which can predispose to ED. Possible mechanisms underlying hyperlipidaemia-induced ED include: (1) upregulation of NADPH oxidase, increased O$_2^-$ production and oxidative stress, (2) increased plasma levels of asymmetric dimethylarginine (ADMA), and (3) oxidation of LDL. ADMA is an endogenous inhibitor of eNOS and competes with L-arginine for the same binding site on eNOS, thus resulting in eNOS uncoupling, increased O$_2^-$ production and hence decreased NO production. Plasma concentrations of ADMA have been reported to be increased in hypercholesterolaemia, and this compound is considered to be both a marker and risk factor of ED.

In addition to scavenging NO, excess O$_2^-$ modifies LDL cholesterol to form oxidised LDL (ox-LDL), which plays a major role in the development of endothelial activation and atherosclerosis. Ox-LDL has been reported to promote ET-1 production, expression of adhesion molecules and chemo-attractants, as well as VSMC migration and proliferation. Furthermore, ox-LDL can be engulfed by macrophages forming foam cells which adhere to the vessel wall and contribute to the initiation of an atherosclerotic plaque.

Both LDL and ox-LDL have been shown to increase the activity of S-adenosylmethionine-dependent methyltransferases, which lead to increased ADMA synthesis. Therefore, LDL and ox-LDL may be accountable for the increased plasma levels of ADMA in hypercholesterolaemia. LDL or ox-LDL can also upregulate caveolin-1 synthesis and thus inhibit eNOS activity (Fig. 4).

**Hypertension**

ED is a prominent underlying feature of hypertension, and patients with hypertension have been shown to demonstrate blunted forearm blood flow in response to vasodilatory stimuli such as acetylcholine and bradykinin, which is indicative of ED. Increased production of ROS and endothelial-derived contracting factors (EDCFs) such as ET-1, angiotensin II, PGH$_3$, and TXA$_3$, and decreased NO bioavailability are all observed in patients with hypertension. Shear stress is known to be one of the most important mechanisms of inducing NO-mediated vasodilation in both the micro- and macrovasculature. However, this response is reduced or absent in hypertensive patients. In addition to this, Iaccarino *et al.* observed decreased protein kinase B (PKB)/Akt-dependent activation of eNOS in a model of spontaneously hypertensive rats (SHR).

In a recent study, the role of oxidative stress and ED in the development of hypertension in spontaneously hypertensive rates was investigated. The results showed that early treatment with the antioxidant resveratrol was associated with reduced oxidative stress markers, improved endothelium-dependent vasodilatation and an attenuation in the development of hypertension in these animals.

**Smoking**

Tobacco smokers exhibit decreased NO bioavailability, increased levels of ox-LDL, and impaired flow-mediated vasodilation, phenomena which are all highly suggestive of ED. Passive smoking has recently also been implicated in impairment of endothelial function. It appears that the harmful effects of smoking on endothelial cells are dose dependent and reversible upon smoking cessation. As with other cardiovascular disease risk factors, oxidative stress appears to be the major mechanistic link between smoking and ED.

Cigarette smoke is rich in free radicals and directly delivers free radicals to the body. Besides being the supplier of free radicals, cigarette smoke facilitates endogenous release of ROS via activation of inflammatory cells. Furthermore, smoking has been reported to decrease the levels of HDL cholesterol, which is known to have anti-endothelial dysfunction and anti-atherosclerotic properties.

**Aging**

Increasing age has been recognised as one of the factors that predisposes to ED. With aging, the ability of the endothelium to produce NO is reduced. Furthermore, some studies have reported reduced expression and activity of eNOS as well as decreased expression of a major downstream target molecule of NO, soluble guanylyl cyclase (sGC) in VSMCs, and its activity in older animals. In addition to the decreased NO production, other endothelial-derived relaxing factors (EDRFs) (prostacyclin and EDHF) are also reduced, while endothelial-derived contracting factors (EDCFs) such as ET-1 and COX-derived prostanoids, and ROS production are increased. Plasma levels of ADMA are inversely correlated with age. Hence, smoking and aging have similar effects on ED. Reduced NO bioavailability will lead to impaired vasodilation and endothelial dysfunction, which will contribute to the development of atherosclerosis. The combination of smoking and aging will be even more detrimental to endothelial function.
are also known to rise with increased age.\textsuperscript{41}

One of the mechanisms contributing to reduced NO levels in aging may be the increased activity of arginase I.\textsuperscript{41-44} Arginase I is an enzyme that catalyses conversion of L-arginine to L-ornithine and urea, and it thus competes with eNOS for L-arginine.\textsuperscript{45} Hence, the increased activity of this enzyme as observed with advancing age may result in uncoupling of eNOS, reduced NO production and hence ED.\textsuperscript{44} Clearly the balance between EDRFs and EDCFs is lost with advancing age, establishing aging as a risk factor for the development of ED. Moreover, aging is often associated with co-morbid conditions such as diabetes, hypertension and hypercholesterolaemia, further exacerbating the risk of developing ED, atherosclerosis and ultimately cardiovascular diseases.\textsuperscript{46}

Proposed mechanisms of ED

Oxidative stress appears to be the common underlying mechanism for the development of ED in all the risk factors discussed above. According to the literature, cardiovascular risk factors are associated with upregulation of ROS sources, especially NADPH oxidase.\textsuperscript{7-20} However, other sources of ROS such as xanthine oxidase, cyclooxygenase (COX) and mitochondria also play a role.\textsuperscript{21} In fact, eNOS per se becomes a potential ROS generator when in the uncoupled state.\textsuperscript{22} Harmful effects of oxidative stress include increasing VSMC proliferation (resulting in thickening of the vascular wall), endothelial cell apoptosis, and increased expression and activity of matrix metalloproteinases, which are involved in the establishment of an atherosclerotic plaque.\textsuperscript{23}

Oxidative stress comprises increased rates of oxidant production and decreased levels of antioxidant activity [e.g. superoxide dismutase (SOD), vitamin C and E, etc.].\textsuperscript{46} Under physiological conditions, the enzyme SOD regulates the levels of $\text{O}_2^–$.\textsuperscript{47} However, increased generation of $\text{O}_2^–$ overwhelms the defensive mechanisms of SOD, leaving $\text{O}_2^–$ free to react with other molecules, particularly NO, for which it has a greater affinity.\textsuperscript{27}

$\text{O}_2^–$ is implicated in the direct induction of ED by the scavenging of NO, leading to the production of the highly reactive and harmful reactive nitrogen species (RNS), peroxynitrite.\textsuperscript{48} In fact, the reaction between $\text{O}_2^–$ and NO has been reported to occur much faster (rate constant $=6.7 \times 10^9 \text{ m}^3 \text{s}^{-1}$) than that of dismutation of $\text{O}_2^–$ by SOD (rate constant $=2.0 \times 10^9 \text{ m}^3 \text{s}^{-1}$).\textsuperscript{49} High levels of peroxynitrite are injurious to the cells, oxidatively damaging DNA, lipids and proteins. In addition to being cytotoxic, peroxynitrite damages the intricate eNOS structure, leading to eNOS uncoupling, which further perpetuates the ED vicious circle\textsuperscript{46} (Fig. 5).

Peroxynitrite has been reported to oxidise the essential cofactor of eNOS, BH$_4$, to its inactive form, trihydrobiopterin radical (BH$_3^*$), which in turn leads to uncoupling of eNOS.\textsuperscript{30,39,51} Furthermore, peroxynitrite may oxidise the zinc thiolate cluster in the centre of the eNOS enzyme, resulting in the loss of the zinc ion and the formation of disulfide bonds between the enzyme monomers, and thus disruption of the binding site for BH$_4$ and L-arginine\textsuperscript{30,52} (Fig. 3). Vitamin C is able to recycle BH$_4$ to BH$_3$\textsuperscript{30,51}, and supplementation with BH$_4$ has been reported to restore endothelial function in conditions such as insulin resistance, hypercholesterolaemia,\textsuperscript{30} diabetes mellitus and essential hypertension, as well as in chronic smokers.\textsuperscript{24}

In addition to peroxynitrite-induced eNOS uncoupling, other oxidants such as hydrogen peroxide have also been shown to uncouple the enzyme. Therefore, during conditions of oxidative stress, eNOS deviates from its role of being an essential regulator of the functioning of the cardiovascular system to being an $\text{O}_2$ releasing enzyme. A vicious circle therefore develops, whereby uncoupled eNOS synthesises $\text{O}_2$ at the expense of NO, further aggravating oxidative stress.

Inflammation is another common underlying mechanism of ED.\textsuperscript{53} Under physiological conditions, the endothelium regulates vascular inflammation (including expression of adhesion molecules and leukocyte adhesion) via the release of NO.\textsuperscript{54} It is therefore more likely that ED will promote sustained vascular inflammation, which is detrimental to the vascular system. However, several studies have reported that inflammation also promotes ED and it is therefore recognised as a novel risk factor for cardiovascular diseases.\textsuperscript{55,56}

There seems to be a causal relationship between oxidative stress and inflammation. Oxidative stress may amplify vascular inflammation signalling pathways,\textsuperscript{57} and conversely inflammatory cells increasingly release $\text{O}_2^–$. Inflammation is often associated with the overexpression of inflammatory cytokines such as tumour necrosis factor-alpha (TNF-\textalpha) and interleukin-1 (IL-1). These inflammatory cytokines in turn prompt endothelial cells or macrophages to express adhesion molecules such as VCAM-1 and ICAM-1, MCP-1, interleukin-6 (IL-6) resulting in a state of endothelial activation, which is a precursor of ED\textsuperscript{58} (Fig. 1).

The role of TNF-\textalpha in ED has received considerable attention in recent years, and is now well appreciated. High levels of TNF-\textalpha have been associated with cardiovascular diseases such as acute myocardial infarction, chronic heart failure, atherosclerosis and myocarditis.\textsuperscript{59} Increased TNF-\textalpha levels are also significantly correlated with obesity, which is an independent risk factor for ED.\textsuperscript{60} This inflammatory cytokine has been reported to promote oxidation of BH$_4$ to BH$_3$, and when in excess, it preferentially combines with NO to produce peroxynitrite with various pathophysiological consequences.
ROS formation via NADPH oxidase and xanthine oxidase.\textsuperscript{29} For example, Gao et al. reported that TNF-\(\alpha\) induces ED via increased NADPH oxidase activity in coronary arterioles of mice with type 2 diabetes.\textsuperscript{41} In addition, TNF-\(\alpha\) has been implicated in the downregulation of eNOS expression (and therefore decreased NO production) by accelerating eNOS mRNA degradation.\textsuperscript{54,56,62} According to Zhang et al., ED observed in myocardial ischaemia–reperfusion injury may be attributable to increased TNF-\(\alpha\) expression via the enhancement of xanthine oxidase activity.\textsuperscript{42}

Other harmful stimuli-induced mechanisms associated with the development of increased oxidative stress and decreased eNOS activation/eNOS uncoupling include activation of cholesterylester transport protein (CETP), downregulation of lipoprotein lipase, downregulation of peroxisome-proliferator activated receptor (PPAR), downregulation of protein kinase A (PKA), activation of caveolin, activation of rho-kinase and downregulation of sphingosine-1-phosphate.\textsuperscript{64}

**Assessment of endothelial function**

**Direct mechanical endothelial function measurements**

Direct endothelial function measurement in humans has the potential to become an important clinical tool in diagnosing or predicting the development of cardiovascular disease in the presence or absence of cardiovascular risk factors. Furthermore, in recognition of evidence pointing towards a pathophysiological link between ED and IHD, a number of human experiments have been conducted in which clinical assessment of ED is explored as a possible predictor or prognostic marker of cardiovascular events.\textsuperscript{60}

An ideal method for the direct measurement of endothelial function should be safe, cost-effective, non-invasive, repeatable, reproducible and standardised between laboratories.\textsuperscript{65} Current methods of assessing endothelial function include flow-mediated dilatation (FMD), forearm plethysmography, finger-pulse plethysmography, pulse curve analysis and quantitative coronary angiography\textsuperscript{60} (Table 2).

In a recent review article, FMD was recognised as a commonly undertaken, non-invasive technique to assess endothelial function.\textsuperscript{66} In this article, a meta-analysis of 14 studies (more than 8 300 subjects) showed that FMD was strongly predictive of future cardiovascular events. Despite the evidence in favour of the independent prognostic value of vascular/endothelial function measurements, the authors conceded that more and larger human studies should be undertaken to confirm this finding.

**Biomarkers**

Although many biomarkers of endothelial function have been identified, only some may have potential clinical use. Therefore, the measurement of endothelial biomarkers remains a tool mainly utilised in the experimental animal and in vitro laboratory setting.

**Reduction of NO bioavailability**

Reduction in endothelial-derived NO production or bioavailability represents a measurable parameter that is suggestive of the development of ED. Laboratory-based studies most often make use of indirect NO measurements (measurements of metabolic products of NO) to confirm ED, such as nitrogen oxide levels\textsuperscript{69} or levels of stable degradation products, nitrite and nitrate.\textsuperscript{46} Many researchers also measure expression and/or activation of eNOS, the main enzymatic source of NO in endothelial cells, to further validate their findings.\textsuperscript{67,68}

In humans, changes in NO production can also be detected in plasma by measurement of NO metabolites. Kiettisanpipop et al. reported a decrease in plasma NO metabolite levels in patients with severe pulmonary hypertension compared to those with moderate hypertension.\textsuperscript{71} Oestrogen replacement therapy has been shown to increase plasma NO levels while decreasing ET-1 levels and thus improving endothelial function in postmenopausal women.\textsuperscript{72} Heiss et al. demonstrated that plasma levels of NO derivatives (nitrosyl/nitroso species) were decreased in patients with endothelial dysfunction.\textsuperscript{73} It remains to be seen, however, whether the measurement of plasma NO or NO-derived metabolites will become a widely used clinical tool with predictive properties.

**ADMA**

ADMA has emerged as a mediator, independent risk factor and, from a clinical perspective, potentially promising marker of ED.\textsuperscript{74} As explained earlier, ADMA is endogenously synthesised via methylation of arginine residues in the nuclear proteins\textsuperscript{76} and competitively inhibits eNOS, resulting in decreased NO production, which may induce eNOS uncoupling. Synthesis

| Method | Brief description |
|--------|------------------|
| Forearm plethysmography | Involves intrabrachial infusion of endothelial-dependent vasodilators such as acetylcholine, meta-choline, substance P and bradykinin, with subsequent measurement of changes in endothelial function of forearm arterioles |
| Flow-dependent dilation of the brachial artery | This method employs a high-resolution ultrasound to quantify flow-mediated dilation of the brachial artery |
| Finger-pulse plethysmography (ENDO-PAT) | A novel non-invasive technique that measures changes of the pulse-wave amplitude during reactive hyperaemia. Low pulse-wave amplitudes are associated with compromised endothelial function and are therefore good predictors of cardiovascular disease |
| Pulse curve analysis | A non-invasive technique that relies on the measure of arterial stiffness to quantify endothelial function |
| Quantitative coronary angiography following intracoronary infusion of acetylcholine | An invasive approach of quantifying endothelial function, which involves intracoronary infusion of the endothelium-dependent vasodilator, acetylcholine, and subsequent measurement of the vaso-motor response |
of ADMA is catalysed by protein arginine methyltransferases (PRMTs) and its degradation is catalysed by dimethylarginine dimethylaminohydrolases (DDAH).77 DDAH levels are often decreased in a variety of cardiovascular diseases, which leads to the upregulation of ADMA. For example, treatment of endothelial cells with TNF-α, ox-LDL and glucose has been reported to diminish the activity of DDAH.85 Furthermore, PRMTs and DDAH are ROS-sensitive; the activity of the DDAH is impaired, whereas the activity of the PRMTs is increased in conditions of oxidative stress.77

Indeed, increased plasma levels of ADMA have been documented in patients with conditions such as hyperlipidaemia, hypertension, coronary artery disease, stroke and end-stage renal disease.77 Furthermore, ADMA was found to be significantly elevated in patients with unstable angina, and reduced plasma levels of ADMA at six weeks post-percutaneous coronary intervention was found to be possibly indicative of a reduced risk of recurrent cardiovascular events.86

A recent study investigated the prognostic value of ADMA with regard to cardiovascular disease and death (fatal or non-fatal myocardial infarction, coronary insufficiency, angina pectoris, stroke or TIA, intermittent claudication or heart failure) in Framingham Offspring study participants.77 Although ADMA was significantly associated with all-cause mortality in this population, the study could not find an association between ADMA and cardiovascular disease incidence.

Circulating endothelial cells and endothelial microparticles

Circulating endothelial cells (CECs), which are mature cells that have detached from the endothelium, represent a novel biomarker of endothelial injury.79 In a healthy person, the endothelium is constantly refurbished at a replication rate of < 1% and levels of CECs are very low. Studies using a flow-activated cell sorter (FACS) isolation technique reported CECs ranging from 50–7900 cells/ml in healthy individuals and up to 39 100 cells/ml in individuals with vascular diseases.79 Potential mechanisms underlying endothelial cell detachment may be mechanical injury, action of proteases and/or cytokines, defective endothelial cell adhesion to the extracellular matrix, cellular apoptosis, and injurious actions of cardiovascular risk factors, such as occur during the induction of ED. Increased levels of CECs are associated with ED, cardiovascular diseases and a variety of other diseases.79 Apoptotic CECs expressing surface marker (CD146) have been reported to be increased in patients with cardiovascular disease.85

Other circulating cellular markers of endothelial injury include endothelial microparticles (EMPs), which are small cell membrane vesicles released into the circulation by activated or apoptotic cells.85 Patients with hypertension and coronary artery disease have been reported to demonstrate high levels of EMPs,85 and according to Tramontano et al., statins can diminish the release of EMPs in cultured coronary endothelial cells.

Nitrotyrosine upregulation

In addition to its ability to directly uncouple the eNOS enzyme, which can lead to ED, peroxynitrite undergoes protonation to form peroxynitrous acid (ONOOH), or it can combine with carbon dioxide (CO₂) to form nitroso-peroxocarboxylate (ONOOCO₂⁻), both of which yield tyrosine-nitrating compounds.80,81 Via formation of these compounds, peroxynitrite leads to nitration (addition of a NO₂ group) of tyrosine residues of proteins, leading to formation of nitrotyrosine.82

Under normal conditions, low levels of free or protein-bound nitrotyrosine are detectable, which may indicate low levels of oxidants and nitrating species produced during physiological processes. However, significant nitrotyrosine upregulation is observed in conditions that are associated with nitrooxidative stress such as inflammation, cardiovascular disease (including ED and atherosclerosis) and neurodegenerative disorders.83 Tyrosine nitrification may modify the structure and function of proteins, leading to alterations in catalytic activity of enzymes, production of antigenic epitopes, and impaired cell signal transduction.85

It has recently been proposed that nitrotyrosine levels can be clinically detected in urine samples using a surface plasmon resonance (SPR) sensor or high-performance liquid chromatography.86 However, nitrotyrosine measurements in the context of ED research remain confined to the experimental laboratory setting.

Other biomarkers of ED/vascular injury

Recently, the European Society of Cardiology Working Group on Peripheral Circulation published a position statement on methods for evaluating endothelial function.87 In this comprehensive review, several biochemical markers and assays that are used to examine different aspects of endothelial function were discussed. The working group mooted plasma ADMA levels as a potential biomarker of endothelial function; however the authors cautioned that currently, direct endothelial function measurements remain a superior indicator and should not be replaced by plasma ADMA level measurements due to inconsistent prognostic data obtained with the latter.

Another biomarker with potential clinical application is oxidised LDL levels; however this biomarker also presents with some limitations. It is difficult to determine ox-LDL levels in vivo and the ability of elevated plasma ox-LDL to independently predict the development of coronary heart disease is still equivocal.

In a recent study on a model of rat carotid injury, proteomic analysis of blood proteins showed significantly differential expression of vitamin D binding protein (VDBP), aldolase A (aldo A) and apolipoprotein E (ApoE) two weeks after injury.88 Reduced circulating levels of all three of these plasma markers were associated with the presence of vascular injury and may represent novel markers of ED; however, further research is necessary.

Summary of assessment of endothelial function

With the development of an ever-increasing number of measurement techniques of endothelial function (both direct mechanical endothelial function assessment and measurement of biomarkers of endothelial function), most authors agree that more and larger human-based studies are necessary to validate their clinical usefulness. The overall objective of such studies should ultimately be to establish standardised protocols allowing for the clinical diagnosis of ED, and quantification of cardiovascular risk, followed by the reversal of ED by means of
anti-ED therapies. We are not there yet. The various endothelial function assessment tools at our disposal should be compared in studies that account for, among others, pathophysiological relevance and reproducibility, predictability in diverse patient populations, ease of use, cost-effectiveness, and risk assessment abilities that are superior to the tools currently in use. 

Another shortcoming in our understanding of the clinical significance of ED is the lack of studies where the effects of therapies that specifically target endothelial biology are investigated. In this regard, promising observations were made in a study which showed that dietary supplementation with the NO-donor, L-arginine significantly improved endothelium-dependent dilatation in young adults with hypercholesterolaemia. Similarly, in another study on rabbits, dietary supplementation with L-arginine prevented hypercholesterolaemia-induced ED by augmentation of NO-production. 

**Progression of ED to atherosclerosis**

ED has emerged as a potentially valuable prognostic tool in predicting the development of atherosclerosis and ultimately IHD. The progression from the early changes observed in compromised vascular endothelium (endothelial activation and dysfunction) to atherosclerosis is complex and multifactorial. The healthy, intact endothelium is a highly selectively permeable barrier and does not promote leukocyte adhesion and invasion, or platelet aggregation and adhesion. However, as the endothelium progresses to a dysfunctional state, vascular homeostasis becomes impaired, leading to reduced anti-oxidant, anti-inflammatory and anti-thrombotic properties (due to reduced NO bioavailability), enhanced endothelial permeability (barrier dysfunction), upregulated pro-inflammatory cytokine levels, and expression of adhesion molecules such as VCAM-1 and ICAM-1, which facilitate leukocyte adhesion to the endothelium. Leukocyte adhesion represents one of the first steps in the initiation of atherosclerosis. After adhering to the endothelium, leukocytes (monocytes and lymphocytes) cross the endothelium and migrate into the intima. Migration to the intima is mediated by chemo-attractants such as monocyte chemotactic protein-1 (MCP-1). Upon reaching the intima, monocytes transform into macrophages and express receptors that facilitate uptake of lipids. Uptake and accumulation of lipids lead to the transformation of macrophages into foam cells, which initiate an atherosclerotic lesion and further enhance release of inflammatory cytokines. Through complex mechanisms, a cascade of events, which begins with the formation of an early atherosclerotic lesion, leading to an advanced lesion characterised by a plaque formation ensues.

**Anti-endothelial dysfunction therapies**

It has been shown that interventions such as lifestyle modification (exercise and diet) and various classes of pharmacological drugs can improve endothelial function, and in some instances reduce the risk of cardiovascular diseases. The anti-ED properties of statins have been extensively studied. Statins such as pravastatin, atorvastatin, simvastatin and fluvastin have all been shown to play an important role in correction of ED by improving endothelium-dependent vasodilation, in addition to their plasma cholesterol-lowering effects.

Indeed, statin-induced eNOS activating effects have been demonstrated in investigations where addition of an eNOS inhibitor (L-NMMA) to pravastatin-treated hypercholesterolaemic patients hampered the endothelium-dependent vasodilation. Moreover, statins have been reported to stimulate activity of PKB/Akt, a major upstream activating signalling molecule of eNOS, and increase stability of eNOS mRNA, thus enhancing eNOS expression.

In addition to statins and NO donors (discussed above), other drugs that have been shown to improve endothelial function include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor (AT1 receptor) blockers, peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, antioxidants and oestrogen replacement. In a recent review article, Balakumar et al. identified potentially novel target sites for the pharmacological improvement of vascular function. These target sites include rho-kinase, poly (ADP ribose) polymerase, protein tyrosine phosphatase (PTPase), Akt, protein kinase A (PKA), caveolin, cholesteryl ester transfer protein (CETP), lipoprotein lipase, sphinogosine-1-phosphate (SIP), advanced glycation end-product (AGE) and transketolase, geranylgeranyltransferase (GGT), epoxide hydrolase and Janus kinase (JAK).

**Conclusion**

In view of the ever-increasing prevalence of ischaemic heart disease in the developed and developing world, it has become imperative to identify and investigate mechanisms of early, potentially reversible pre-atherosclerotic changes in the endothelium. To date, the most clearly defined and well-understood early precursor of atherosclerosis is ED. In fact ED can be regarded as the *primum movens* of atherosclerotic disease. Several cellular mechanisms and markers of ED that could potentially lead to the development of early detection and therapeutic interventions have been determined. However, more research aiming at improving our understanding of ED is necessary in order to establish its detection and reversal as essential and routinely utilised future tools in the prevention of IHD.

This study was sponsored in part by the Medical Research Council (MRC) of South Africa, National Research Fund (NRF) of South Africa and the Harry Crossley Foundation, University of Stellenbosch.

**References**

1. Steyn K. Heart Disease in South Africa. In: Fourie JM (ed). Chronic diseases of lifestyle unit. Medical Research Council (MRC) media data document. MRC, 2007.
2. World Health Organisation (WHO). Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: WHO, 2009.
3. Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol 2007; 60(2): 184–190.
4. Choi D, Hwang K-C, Lee K-Y, Kim Y-H. Ischemic heart disease: current treatments and future. J Conr Release 2009; 140: 194–202.
5. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115: 1285–1295.
6. Yang G, Lucas R, Caldwell R, Yao L, Romero MJ, Caldwell RW. Novel mechanisms of endothelial dysfunction in diabetes. J Cardiovasc Dis Res 2010; 1(2): 59–63.
7. Chabara N. Endothelial dysfunction – A predictor of atherosclerosis. Internet J Med Update 2009; 4(1): 33–41.
8. Biji M. Endothelial activation, endothelial dysfunction and premature...
atherosclerosis in systemic autoimmune disease. *Neth J Med* 2003; 60: 273–277.

9. Rabelink TJ, De Boer CH, van Zonneveld AJ. Endothelial activation and circulating markers of endothelial activation in kidney disease. *Nat Rev Nephrol* 2010; 6: 404–414.

10. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherothrombotic risk. *Arterioscler Thromb Vasc Biol* 2003; 23: 168–175.

11. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharon JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. *Cardiovasc Diabetol* 2006; 5: 4.

12. Strijdom H, Lochner A. Cardiac endothelium: More than just a barrier! *SA Heart* 2009; 6(3): 174–185.

13. Strijdom H, Chamane N, Lochner A. Nitric oxide in the cardiovascular system: a simple molecule with complex actions. *Cardiovasc J Afr* 2009; 20: 303–310.

14. Bruckdorfer R. The basics about nitric oxide.

15. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. *Hypertension* 1988; 12: 365–372.

16. Balligand J-L, Cannon PJ. Nitric oxide synthases and cardiac muscle: autocrine and paracrine influences. *Arterioscler Thromb Vasc Biol* 1997; 17: 1846–1858.

17. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. *Front Biosci* 2009; 14: 1–18.

18. Alderdt WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. *Biochem J* 2001; 357: 593–615.

19. Dudzinski D, Michel T. Life history of eNOS: partners and pathways. *Cardiovasc Res* 2007; 75(2): 247–260.

20. Förstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Curr Hypertens Rep* 2005; 7: 96–102.

21. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. *Br J Pharmacol* 2009; 157: 527–536.

22. Sawamura T. LOX-1, a lectin-type oxidized LDL receptor identified form endothelial cells, in endothelial dysfunction. *Int Congr 2004; 1262: 531–534.

23. Böger RH, Bode-Böger S, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction, its role in hypercholesterolemia. *Circulation* 1998; 98: 1842–1847.

24. Böger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. *Atherosclerosis Suppl* 2003; 4: 1–3.

25. Zeigb S, Li Z, Wagner S, et al. Effect of the ox-LDL binding protein Fe-CD68 on plaque extension and vulnerability in atherosclerosis. *Circ Res* 2011; 108(6): 695–703.

26. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium *Circ Res* 1992; 70: 119–1197.

27. Warnholtz A, Mollnau H, Ölzle M, et al. Antioxidants and endothelial dysfunction in hyperlipidaemia. *Curr Hypertens Rep* 2001; 3: 53–60.

28. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation* 2004; 109: 27–32.

29. Amod NB, Vita JA. Endothelial dysfunction in atherosclerosis: mechanisms of impaired nitric oxide bioactivity. In: Loscalzo J (ed). *Molecular Mechanisms of Atherosclerosis*. London: Taylor and Francis 2005: 95–110.

30. Bharit SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. *Eur J Pharmacol* 2011; 671(1-3): 258–264.

31. Tang EH, Vanhoutte PM. Endothelial dysfunction: a strategic target in the treatment of hypertension? *Pflugers Arch* 2010; 459(6): 995–1004.

32. Paniagua OA, Bryant MB, Panza JA. Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients. *Circulation* 2001; 103: 1752–1758.

33. Iaccarino G, Ciccarelli M, Sorrentino D, et al. AKT participates in endothelial dysfunction in hypertension. *Circulation* 2004; 109: 2587–2593.

34. Purank R, Celermajer DS. Smoking and endothelial function. *Progr Cardiovasc Dis* 2003; 45: 443–458.

35. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. *Circulation* 2005; 111: 2684–2698.

36. Burke A, FitzGerald GA. Oxidative stress and smoking-induced vascular injury. *Progr Cardiovasc Dis* 2003; 46: 79–90.

37. Antoniades C, Tousoulis D, Stefanadis C. Smoking in Asians: it doesn’t stop at vascular endothelium. *Int J Cardiol* 2008; 128: 151–153.

38. Katusis ZS. Mechanisms of endothelial dysfunction induced by aging, role of arginine I. *Circ Res* 2007; 101: 640–641.

39. Herrera MD, Mingorance C, Rodrguez-Rodrguez G, et al. Endothelial dysfunction and aging: an update. *Ageing Res Rev* 2010; 9: 142–152.

40. Vanhoutte PM. Ageing and endothelial dysfunction. *Eur Heart J Suppl* 2002; 4: A8–A17.

41. Pennathur S, Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. *Curr Diabetes Rep* 2007; 7: 257–264.

42. Landmesser U, Harrison DG, Drexler H. Oxidant stress – a major cause of reduced endothelial nitric oxdate availability in cardiovascular disease. *Eur J Clin Pharmacol* 2006; 63: 13–19.

43. Yokoyama M. Oxidant stress and atherosclerosis. *Curr Opin Pharmacol* 2004; 4: 110–115.

44. Huang PL. Endothelial nitric oxide synthase and endothelial dysfunction. *Curr Hypertens Rep* 2003; 5: 473–480.

45. Kuzkaya N, Weismann N, Harrison DG, et al. Interaction of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols. *J Biol Chem* 2003; 278: 22546–22554.

46. Katusis ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? *Am J Physiol Heart Circ Physiol* 2001; 281: 981–986.

47. Zhou M-H, Shi C, Cohen RA, OXidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. *J Clin Invest* 2002; 109: 817–826.

48. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation* 2002; 105: 1135–1143.

49. Osto E, Cosentino F. The role of oxidative stress in endothelial dysfunction and vascular inflammation. In: Ignarro LJ (ed). *Nitric Oxide: Biology and Pathobiology* 2nd edn. London: Academic Press 2010: 705–754.

50. Szmitko PE, Wang C-H, Weisel RD, et al. New markers of inflammation and endothelial cell activation, part 1. *Circulation* 2003; 108; 1917–1923.

51. Madamanchi NR, Vendrow A, Runge MS. Oxidative stress and vascular disease. *Arterioscler Thromb Vasc Biol* 2005; 25: 29–38.

52. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. *Circ Res* 2001; 89: 763–771.

53. Meldrum DR. Tumor necrosis factor in the heart. *Am J Physiol Regulatory Integrative Comp Physiol* 1998; 274: 577–595.

54. Fain JN, Bahouth SW, Madan AK. TNF α-release by the nonfat cells of human adipose tissue. *Int J Obes* 2004; 28: 616–622.

55. Zhang H, Park Y, Wu J, et al. Role of TNF-α in vascular dysfunction. *Clin Sci* 2009; 116: 219–230.

56. Gao X, Belmadani S, Picchi A, et al. Tumor necrosis factor-α induces endothelial dysfunction in Leprdb mice. *Circulation* 2007; 115: 245–254.
62. Stenvinkel P. Endothelial dysfunction and inflammation – is there a link? *Nephrol Dial Transplant* 2001; 16: 1968–1971.

63. Zhang C, Xu X, Potter BJ, Wang W, et al. TNF-α contributes to endothelial dysfunction in ischemia/reperfusion injury. *Arterioscler Thromb Vasc Biol* 2006; 26: 475–480.

64. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. *Toxicology* 2008; 245(1–2): 49–64.

65. Münzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis and prognostic implication of endothelial dysfunction. *Ann Med* 2008; 40: 180–196.

66. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? *Hypertension* 2011; 57(3): 363–369.

67. Kim F, Gallis B, Corson MA. TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. *Am J Physiol Cell Physiol* 2001; 280(5): C1057–1065.

68. Bove K, Neumann P, Gertzberg N, Johnson A. Role of eNOS-derived NO in mediating TNF-induced endothelial barrier dysfunction. *Am J Physiol Lung Cell Mol Physiol* 2001; 280(5): L914–922.

69. Xia Z, Luo T, Liu HM, Wang F, Xia ZY, Irwin MG, Vanhoutte PM. Tumor necrosis factor-alpha toxicity to human endothelial cells in culture: prevention by propofol. *J Cardiovasc Pharmacol* 2010; 55(4): 358–367.

70. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. L-arginine enhances nitrative stress and exacerbates tumor necrosis factor-alpha toxicity to human endothelial cells in culture. *Am J Physiol Lung Cell Mol Physiol* 2001; 280(5): H1115–1121.

71. John S, Schlaich M, Langefelm M, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. *Circulation* 2009; 119(12): 1592–1600.

72. Boos CJ, Lip GYH, Blann AD. Circulating endothelial cells in cardiovascular disease. *J Am Coll Cardiol* 2006; 48: 1538–1547.

73. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. *Clin Chim Acta* 2006; 373: 17–26.

74. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-functional alteration or just a biomarker? *Free Radic Biol Med* 2008; 45: 357–366.

75. Hurst JK. Whence nitrotyrosine? *J Clin Invest* 2002; 109: 1287–1289.

76. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 2007; 87: 315–424.

77. Jin J, Wang C, Tao Y, et al. Determination of 3-nitrotyrosine in human urine samples by surface plasmon resonance immunoassay. *Sensors Actuators B* 2011; 153: 164–169.

78. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection and therapeutic consideration. *Curr Opin Cardiol* 2004; 19: 488–493.

79. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. *Eur J Cardiovasc Prev Rehabil* 2011 Mar 11. [Epub ahead of print].

80. Huang NF, Kurpinski K, Fang Q, Lee RJ, Li S. Proteomic identification of biomarkers of vascular injury. *Am J Transl Res* 2011; 3(2): 139–148.

81. Clarkson P, Adams MR, Poe WJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. *J Clin Invest* 1996; 97(8): 1989–1994.

82. Javanmard SH, Nematzadeh MA, Sanei MH. Early prevention by L-arginine attenuates coronary atherosclerosis in a model of hypercholesterolemic animals; no positive results for treatment. *Nutr Metab (Lond)* 2009; 6: 13.

83. Yang Z, Ming X-Z. Recent advances in understanding endothelial dysfunction in atherosclerosis. *Clin Med Res* 2006; 4: 53–65.

84. Ruberg FL, Loscalzo J. Inflammation and atherothrombosis. In: *Clarkson P, Adams MR, Poe WJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest* 1996; 97(8): 1989–1994.

85. Widlansky ME, Gokce N, Keaney JF, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. *Ann Intern Med* 1998; 128: 285–288.

86. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. *Clin Chim Acta* 2006; 373: 17–26.

87. Hurst JK. Whence nitrotyrosine? *J Clin Invest* 2002; 109: 1287–1289.

88. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 2007; 87: 315–424.

89. Jin J, Wang C, Tao Y, et al. Determination of 3-nitrotyrosine in human urine samples by surface plasmon resonance immunoassay. *Sensors Actuators B* 2011; 153: 164–169.

90. Liu ET, Sander CA, Budoff MJ, et al. Pathophysiology, diagnosis and prognostic implication of endothelial dysfunction. *Ann Med* 2008; 40: 180–196.

91. Croft JJ, Neal P, Weymouth J, et al. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. *Toxicology* 2008; 245(1–2): 49–64.

92. Xia Z, Luo T, Liu HM, Wang F, Xia ZY, Irwin MG, Vanhoutte PM. Tumor necrosis factor-alpha toxicity to human endothelial cells in culture: prevention by propofol. *J Cardiovasc Pharmacol* 2010; 55(4): 358–367.

93. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. *Am J Physiol Heart Circ Physiol* 2007; 293(2): H1115–1121.

94. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. *Eur J Cardiovasc Prev Rehabil* 2011 Mar 11. [Epub ahead of print].

95. Huang NF, Kurpinski K, Fang Q, Lee RJ, Li S. Proteomic identification of biomarkers of vascular injury. *Am J Transl Res* 2011; 3(2): 139–148.

96. Clarkson P, Adams MR, Poe WJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. *J Clin Invest* 1996; 97(8): 1989–1994.

97. Widlansky ME, Gokce N, Keaney JF, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. *Ann Intern Med* 1998; 128: 285–288.

98. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. *Clin Chim Acta* 2006; 373: 17–26.

99. Yang Z, Ming X-Z. Recent advances in understanding endothelial dysfunction in atherosclerosis. *Clin Med Res* 2006; 4: 53–65.

100. Ruberg FL, Loscalzo J. Inflammation and atherothrombosis. In: *Loscalzo J (ed). Molecular Mechanisms of Atherosclerosis*. London: Taylor and Francis 2005: 45–60.

101. Libby P. Changing concepts of atherogenesis. *J Intern Med* 2000; 247: 349–358.

102. Widlansky ME, Gokee N, Keaney JF, et al. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003; 42: 1149–1160.

103. John S, Schlaich M, Langefeld M, et al. Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double blind study. *Circulation* 1998; 98: 211–216.